Neuland Laboratories Ltd.

NSE: NEULANDLAB BSE: 524558 SECTOR: Pharmaceuticals & Drugs  32k   163   16

1482.05
-36.40 (-2.40%)
NSE: 07 Oct 03:59 PM

Price Summary

Today's High

₹ 1536.65

Today's Low

₹ 1467.25

52 Week High

₹ 1874

52 Week Low

₹ 967

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1901.45 Cr.

Enterprise Value

2113.41 Cr.

No. of Shares

1.28 Cr.

P/E

29.38

P/B

2.25

Face Value

₹ 10

Div. Yield

0.34 %

Book Value (TTM)

₹  658.23

CASH

18.99 Cr.

DEBT

230.95 Cr.

Promoter Holding

36.22 %

EPS (TTM)

₹  50.45

Sales Growth

1.51%

ROE

7.86 %

ROCE

9.44%

Profit Growth

-20.87 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year1.51%
3 Year12.56%
5 Year10.44%

Profit Growth

1 Year-20.87%
3 Year57.88%
5 Year6.49%

ROE%

1 Year7.86%
3 Year6.98%
5 Year5.87%

ROCE %

1 Year9.44%
3 Year10.04%
5 Year7.62%

Debt/Equity

0.2767

Price to Cash Flow

32.45

Interest Cover Ratio

7.05731266303059

CFO/PAT (5 Yr. Avg.)

2.05488546034608

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2022 36.22 0
Mar 2022 36.22 0
Dec 2021 36.22 4.3
Sep 2021 36.22 4.3
Jun 2021 36.22 4.3
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 57.8831186891491% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 66.5701297150877 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.05488546034608.

 Limitations

  • The company has shown a poor revenue growth of 12.5641848556314% for the Past 3 years.
  • Company has a poor ROE of 6.98140909744505% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022
Net Sales 200.89 257.85 236.47 255.87 221.17
Total Expenditure 175.29 215.06 204.18 217.16 192.69
Operating Profit 25.6 42.79 32.29 38.71 28.48
Other Income 2.06 0.29 1.9 0.63 0.51
Interest 3.84 3.56 3.32 2.77 2.86
Depreciation 11.83 11.98 12.78 12.45 12.8
Exceptional Items 0 0 0 0 0
Profit Before Tax 11.99 27.53 18.1 24.12 13.33
Tax 3.34 7.21 5.37 2.3 3.49
Profit After Tax 8.65 20.33 12.73 21.83 9.84
Adjusted EPS (Rs) 6.7 15.76 9.87 16.92 7.63

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 527.41 666.83 762.71 936.91 951.08
Total Expenditure 477.38 608.96 661.25 790.47 808.88
Operating Profit 50.03 57.87 101.46 146.44 142.19
Other Income 4.53 3.49 3.89 16.09 2.08
Interest 18.92 15.66 21.57 17.9 13.49
Depreciation 22.1 25.86 31.28 39.68 49.04
Exceptional Items 0 0 0 0 0
Profit Before Tax 13.54 19.84 52.5 104.96 81.74
Tax 1.73 3.69 36.62 24.67 18.21
Net Profit 11.81 16.14 15.88 80.29 63.53
Adjusted EPS (Rs.) 13.29 12.58 12.38 62.58 49.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 8.95 12.9 12.9 12.9 12.9
Total Reserves 545.83 682.68 692.64 768.98 822.67
Borrowings 103.49 60.72 77.37 88.13 104.25
Other N/C liabilities 42.29 42.41 84.83 80.54 74.17
Current liabilities 370.38 331.19 361.99 372.96 368.13
Total Liabilities 1070.94 1129.9 1229.74 1323.52 1382.12
Assets
Net Block 445.01 511.67 622.75 696.92 747.7
Capital WIP 126.09 104.47 23.75 17.25 20.46
Intangible WIP 0 0 0 0 0
Investments 30.37 30.37 30.33 19.5 20.31
Loans & Advances 22.52 30.45 35.78 41.66 12.42
Other N/C Assets 0.22 0 3.3 0 0
Current Assets 446.73 452.93 513.83 548.18 581.23
Total Assets 1070.94 1129.9 1229.74 1323.52 1382.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 13.54 19.84 52.5 104.96 81.74
Adjustment 40.35 38.93 58.14 40.17 64.37
Changes in Assets & Liabilities -39.2 15.92 -49.3 49.34 -66.99
Tax Paid -3.17 -5.09 -4.7 -5.19 -20.53
Operating Cash Flow 11.52 69.6 56.63 189.28 58.6
Investing Cash Flow -116.29 -77.22 -48.68 -84.42 -93.72
Financing Cash Flow 104.86 11.98 -5.48 -113.66 37.72
Net Cash Flow 0.09 4.36 2.47 -8.8 2.6

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Promoters 36.22 36.22 36.22 36.22 36.22
ramamohan rao davu... - - - - 24.77
davuluri rama moha... 24.77 24.77 24.77 24.77 -
davuluri vijaya rao 4.78 4.78 4.78 4.78 4.78
davuluri sucheth r... 2.49 2.49 2.49 2.49 2.49
davuluri saharsh r... 1.90 1.90 1.90 1.90 1.90
d saharsh rao - - - - -
davuluri rohini ni... 1.27 1.27 1.27 1.27 1.27
usha rani reddy ch... - - - - -
gannabathula venka... 0.35 0.35 0.35 0.35 0.35
gannabathula veer... 0.25 0.24 0.24 0.24 -
gannabathula veera... - - - - 0.24
gannabathula subba... 0.17 0.04 0.04 - -
ganabathula uma ba... 0.05 0.05 0.05 0.05 -
gannabathula uma b... - - - - 0.05
PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Investors 63.78 63.78 63.78 63.78 63.78
malabar india fund... 9.95 9.95 9.95 9.95 9.95
steadview capital... - - - - 9.90
steadview capital ... 9.90 9.90 9.90 9.90 -
malabar value fund 4.43 4.43 4.43 4.43 4.43
icici prudential p... 1.76 1.89 1.89 1.91 1.91
abg capital 3.71 3.71 3.71 3.71 3.71
ltr focus fund 2.07 2.07 2.97 - -
matthews india fund - - - - -
mukul mahavir agra... - - - - -
rohinton soli scre... 2.26 2.26 2.26 2.26 2.26
icg q limited 1.15 1.15 1.15 1.56 1.95
infina finance pri... 1.00 1.15 1.32 1.73 2.06
sbi healthcare opp... 2.03 2.03 2.03 - -
kedia securities p... - - - - 1.95
l and t mutual fun... - - - - -
iepf - - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Neuland Laboratories informs about newspaper publication4 Aug 2022, 3:00PM Neuland Laboratories - Quaterly Results3 Aug 2022, 1:45PM Neuland Laboratories - Quaterly Results3 Aug 2022, 1:45PM Neuland Laboratories - Quaterly Results3 Aug 2022, 1:45PM Neuland Laboratories informs about annual report8 Jul 2022, 12:18PM Neuland Laboratories informs about newspaper publication22 Jun 2022, 4:47PM Neuland Laboratories informs about AGM 17 Jun 2022, 12:18PM Neuland Laboratories - Quaterly Results10 May 2022, 4:48PM Neuland Laboratories - Quaterly Results10 May 2022, 4:48PM Neuland Laboratories - Quaterly Results10 May 2022, 4:48PM Neuland Laboratories informs about earnings call details5 May 2022, 3:01PM Neuland Laboratories informs about change in name of share transfer agent 17 Mar 2022, 4:49PM Neuland Laboratories informs about newspaper publication17 Mar 2022, 4:44PM Neuland Laboratories informs about newspaper publication14 Mar 2022, 1:14PM Neuland Laboratories informs about newspaper publication14 Mar 2022, 10:53AM Neuland Laboratories - Quaterly Results1 Feb 2022, 2:35PM Neuland Laboratories - Quaterly Results1 Feb 2022, 2:35PM Neuland Laboratories - Quaterly Results1 Feb 2022, 2:35PM Neuland Laboratories informs about demise of independent director10 Dec 2021, 2:53PM Neuland Laboratories informs about earnings call25 Oct 2021, 1:01PM Neuland Laboratories submits annual secretarial compliance certificate12 May 2021, 4:38PM Neuland Laboratories informs about newspaper publication12 May 2021, 4:30PM Neuland Laboratories informs about disclosure2 Mar 2021, 1:12PM Neuland Laboratories informs about press release4 Aug 2020, 3:11PM Neuland Laboratories receives EIR from USFDA for Hyderabad facility 8 May 2020, 9:08AM Neuland Laboratories submits RTA certificate23 Apr 2020, 3:25PM

Neuland Laboratories Stock Price Analysis and Quick Research Report. Is Neuland Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Neuland Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 58.5975 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Neuland Laboratories has a Debt to Equity ratio of 0.2767 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Neuland Laboratories , the EPS growth was -20.8749173113981 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Neuland Laboratories has OPM of 14.9508357160717 % which is a bad sign for profitability.
     
  • ROE: Neuland Laboratories have a poor ROE of 7.86481170366931 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Neuland Laboratories

X